根据年龄,功能和体重指数分层的抗糖尿病药物的发展趋势:来自全国索赔数据库的见解
Kazuki Aoyama1, Akira Okada2, Hidehiro Kaneko3,4
1Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Diabetes, obesity & metabolism
|November 2, 2025
概括
在日本,从2015年到2024年,用于2型糖尿病的-葡萄糖共运输体2抑制剂 (SGLT2i) 的处方显著增加. 在各种患者群体中,SGLT2i的使用正在增加,这表明临床采用范围更广.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病是一个日益严重的全球健康问题.
- 抗糖尿病药物处方模式需要持续监测.
- 了解趋势对于优化患者护理和资源配置至关重要.
研究的目的:
- 分析日本抗糖尿病药物的处方趋势.
- 根据患者特征对这些趋势进行分层.
- 评估新的抗糖尿病药物的现实世界的整合.
主要方法:
- 一个大规模的日本数据库 (2015-2024) 的回顾性分析.
- 包括接受抗糖尿病处方的2型糖尿病成年人.
- 根据年龄,性别,高频率,eGFR,BMI,HbA1c和临床环境分层的药物类别评估年度处方率.
主要成果:
- -葡萄糖共载体2抑制剂 (SGLT2i) 的处方从2015年的4.1%升至2024年的38.9%.
- 在年轻人 (<65岁),高血压患者,低EGFR (<30) 和肥胖个体中观察到高SGLT2i处方率.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 呈现较低但增长的趋势,特别是在年轻,肥胖的患者中.
结论:
- 在日本,SGLT2i的使用在不同患者资料中显著增加.
- 这些发现支持SGLT2i在现实世界2型糖尿病管理中的广泛整合.
- 这项研究为老龄化人口的糖尿病护理提供了见解.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Oral Hypoglycemic Agents: Glinides
585
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
585
Insulin: Dosing Regimen and Adverse Effects
670
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
670
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
229
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
229
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Management and Pharmacotherapy
856
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
856


